1599-49-1 Purity
97%
If you have any other questions or need other size, please get a quote.
Specification
Arthanari, Saravanakumar, et al. Artificial cells, nanomedicine, and biotechnology, 2016, 44(3), 847-852.
The third-generation fluoroquinolone antibiotic gatifloxacin demonstrates broad-spectrum antibacterial activity and specifically targets Gram-positive bacteria including penicillin-resistant Streptococcus pneumoniae. Researchers produced hydrophilic polyvinyl alcohol-sodium alginate (PVA-SA) composite nanofibers through electrospinning technology and obtained controlled drug release by actively loading gatifloxacin hydrochloride (GH).
· PVA-SA-GH Nanofiber Formulation
Preformulation of sodium alginate (SA) (2 wt %)/polyvinyl alcohol (PVA) (10 wt %) composite (2/8, 3/7 and 4/6) nanofibers was studied. Finally, the optimal ratio (3/7) was used to load gatifloxacin hydrochloride (GH) (1wt %), and it was found that smooth fibers with uniform structure were formed. The drug was loaded by active loading, and the encapsulation efficiency was 95%.
· Drug Release Behavior
The in vitro release curves showed that the drug was controlled and sustained released from the gatifloxacin-loaded PVA-SA composite nanofibers within 6 h. In addition, the thickness of the nanofibers greatly affected the initial release and drug release rate.
Sharma, Namrata, et al. Eye & Contact Lens, 2012, 38(5), 295-299.
Gatifloxacin functions as a broad-spectrum fluoroquinolone antibiotic which demonstrates strong effectiveness against typical ocular pathogens while producing low corneal epithelial toxicity. The medication functions as a powerful antibiotic with coverage against nearly all typical ocular pathogens. This work evaluated the clinical and microbiological characteristics of eye donors and the efficacy of 0.3% gatifloxacin hydrochloride on donor corneal microbial decontamination.
· Evaluation Methods
A randomized clinical trial prospectively analyzed 513 donors and 1,026 corneas at the National Eye Bank of a tertiary care hospital during one year. The donor eyes received a treatment of 5% povidone-iodine alongside 0.4% amikacin sulfate and 0.3% gatifloxacin hydrochloride after grading.
· Evaluation Results
The cultures showed positive results in 57.6% (591/1026) of the eyes with Pseudomonas spp. being the most common organism at 53% and coagulase-negative Staphylococci at 24%. Povidone-iodine and amikacin treatment led to a significant drop in culture positivity rates with P-values of 0.002 for the right eye and 0.004 for the left eye and this reduction intensified when gatifloxacin was included (P=0.001). Gatifloxacin demonstrated effectiveness against Pseudomonas (93%), coagulase-negative Staphylococci (96.3%), Staphylococcus aureus (90.5%), enterococci, and gram-negative bacilli. Notably, multidrug-resistant Pseudomonas spp. was also susceptible to polymyxin-B. The combination of gatifloxacin hydrochloride and amikacin sulfate proves advantageous for decontaminating donor eyes.
The molecular formula of gatifloxacin hydrochloride is C19H23ClFN3O4.
Some synonyms for gatifloxacin hydrochloride are 121577-32-0, 160738-57-8, Gatifloxacin HCl, and Gatifloxacin (hydrochloride).
The molecular weight of gatifloxacin hydrochloride is 411.9 g/mol.
The IUPAC name of gatifloxacin hydrochloride is 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydrochloride.
The InChI of gatifloxacin hydrochloride is InChI=1S/C19H22FN3O4.ClH/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26;/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26);1H.
The InChIKey of gatifloxacin hydrochloride is GQYBNVXJQVIRGC-UHFFFAOYSA-N.
The canonical SMILES of gatifloxacin hydrochloride is CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F.Cl.
The CAS number of gatifloxacin hydrochloride is 121577-32-0.
The hydrogen bond donor count of gatifloxacin hydrochloride is 3.
The hydrogen bond acceptor count of gatifloxacin hydrochloride is 8.
Please kindly note that our products are for research use only.
Download